These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 23483818)

  • 1. From fatty liver to fibrosis: a tale of "second hit".
    Basaranoglu M; Basaranoglu G; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1158-65. PubMed ID: 23483818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.
    Engin A
    Adv Exp Med Biol; 2024; 1460():539-574. PubMed ID: 39287864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron overload in nonalcoholic steatohepatitis.
    Fujita N; Takei Y
    Adv Clin Chem; 2011; 55():105-32. PubMed ID: 22126026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etiopathogenesis of nonalcoholic steatohepatitis.
    Chitturi S; Farrell GC
    Semin Liver Dis; 2001; 21(1):27-41. PubMed ID: 11296694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis.
    Ucar F; Sezer S; Erdogan S; Akyol S; Armutcu F; Akyol O
    Redox Rep; 2013; 18(4):127-33. PubMed ID: 23743495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model.
    Matsunami T; Sato Y; Ariga S; Sato T; Shimomura T; Kashimura H; Hasegawa Y; Yukawa M
    Metabolism; 2011 Jun; 60(6):805-14. PubMed ID: 20846698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats.
    Stärkel P; Sempoux C; Leclercq I; Herin M; Deby C; Desager JP; Horsmans Y
    J Hepatol; 2003 Oct; 39(4):538-46. PubMed ID: 12971963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury.
    Serviddio G; Bellanti F; Tamborra R; Rollo T; Capitanio N; Romano AD; Sastre J; Vendemiale G; Altomare E
    Gut; 2008 Jul; 57(7):957-65. PubMed ID: 18308829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial dysfunction in nonalcoholic steatohepatitis.
    Serviddio G; Bellanti F; Vendemiale G; Altomare E
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):233-44. PubMed ID: 21476918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways of nonalcoholic fatty liver disease development and progression.
    Bessone F; Razori MV; Roma MG
    Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.
    Ipsen DH; Skat-Rørdam J; Tsamouri MM; Latta M; Lykkesfeldt J; Tveden-Nyborg P
    Mol Genet Genomics; 2019 Jun; 294(3):649-661. PubMed ID: 30759275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.
    Begriche K; Igoudjil A; Pessayre D; Fromenty B
    Mitochondrion; 2006 Feb; 6(1):1-28. PubMed ID: 16406828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.
    Boland ML; Oldham S; Boland BB; Will S; Lapointe JM; Guionaud S; Rhodes CJ; Trevaskis JL
    World J Gastroenterol; 2018 Apr; 24(16):1748-1765. PubMed ID: 29713129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
    Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
    Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis.
    Nagata K; Suzuki H; Sakaguchi S
    J Toxicol Sci; 2007 Dec; 32(5):453-68. PubMed ID: 18198478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease.
    Nomura K; Yamanouchi T
    J Nutr Biochem; 2012 Mar; 23(3):203-8. PubMed ID: 22129639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.